Tumor-Informed Circulating Tumor DNA Monitoring for Predicting Outcomes in Patients With Head and Neck Squamous Cell Carcinoma.
Detecting circulating tumor DNA after head-and-neck cancer treatment predicts which patients face higher recurrence risk.
Here, we evaluated circulating tumor DNA (ctDNA) testing post-definitive treatment to detect molecular residual disease (MRD) and predict outcomes in patients with HNSCC. In patients with stage I to IV HNSCC, ctDNA-based MRD positivity after definitive local therapy and adjuvant treatment is associated with disease recurrence and poor survival outcomes.
What the study was
- Study design
- Journal article (design unspecified)
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Advances in radiation oncology
Why it surfaced
⚪ PROMISING_PRELIMINARY — Promising but preliminary; Watchlist: Early cancer detection (liquid biopsy, ctDNA, cfDNA); Design: Journal article (design unspecified); species: human
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.